Top Doctors To Present Results Of FDA Clinical Trial Of Guided Therapeutics' Cervical Cancer Detection Technology At Scientific Meeting

Results of the U.S. Food and Drug Administration (FDA) pivotal clinical trial for the Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP) LightTouch™ Non-invasive Cervical Cancer Detection System are scheduled to be presented by five leading doctors at the American Society for Colposcopy and Cervical Pathology biennial meeting, March 24 - 27, 2010, in Las Vegas.


"Having five peer-reviewed presentations, submitted by recognized experts from nine leading medical institutions, is a testament to the potential for our technology to have a positive affect on women's health," said Mark L. Faupel, Ph.D., President and CEO of GT. "We are pleased that the presentation authors, all of whom are leaders in women's health care, support the LightTouch technology and have agreed to speak to its potential for the early detection of cervical cancer."


In addition to the five peer-reviewed presentations that are scheduled to be published in the meeting proceedings, GT will have a working LightTouch system, including the single-use calibration and patient interface, on display.


The presentation abstract titles and authors are:


Multimodal Spectroscopy As A Triage Test For Women At Risk For Cervical Neoplasia: Results Of A 1,607 Subject Pivotal Trial


Twiggs LB, Chakhtoura NA, University of Miami, Miami, Florida, Werner CL, Griffith WF, University of Texas Southwestern Medical Center, Dallas, Texas, Flowers LC, University of Emory School of Medicine, Atlanta, Georgia, Lashgari M, University of Connecticut, Hartford, Connecticut, Ferris DG, Medical College of Georgia, Augusta, Georgia, Winter ML, Orange Coast Women's Medical Group, Laguna Hills, California, Sternfeld DR, Saddleback Women's Medical Group, Laguna Hills, California, Burnett AF, University of Arkansas, Little Rock, Arkansas, Wilkinson EJ, University of Florida, Gainesville, Florida, Raab SS, University of Colorado, Denver, Colorado



Multimodal Spectroscopy As A Triage Test For Women At Risk For Cervical Neoplasia: Results For Adolescent Subjects


Flowers, LC, Tadros, TS; Emory University School of Medicine, Atlanta, Georgia



Multimodal Spectroscopy As A Triage Test For Women At Risk For Cervical Neoplasia: Histopathology Review Procedures And Results


Wilkinson EJ, Raab SS; University of Florida, Department of Pathology, Gainesville, Florida, University of Colorado at Denver and Health Sciences Center, Department of Pathology, Denver, Colorado



Multimodal Spectroscopy As A Triage Test For Women At Risk For Cervical Neoplasia: Results Of Follow Up Data


Chakhtoura NA, Twiggs LB, University of Miami, Miami, Florida, Wilkinson EJ, University of Florida, Gainesville, Florida, Raab SS, University of Colorado, Denver, Colorado



Multimodal Spectroscopy As A Triage Test For Women At Risk For Cervical Neoplasia: Experience With A Low Cost Commercial Prototype


Winter ML, Sternfeld DR, Orange Coast Women's Medical Group, Laguna Hills, CA, Saddleback Women's Medical Group, Laguna Hills, CA
The 2010 biennial meeting of the American Society for Colposcopy and Cervical Pathology is planned for March 24 - 27, 2010, at the Green Valley Ranch Resort in Las Vegas, Nevada. For more information, visit asccp.


Source

Guided Therapeutics